Houston Principal Ramy Hanna was quoted in an article by Law360 titled, "Fed. Circ. Gene Therapy Ruling Gives Rare Eligibility Clarity." The article discusses the Federal Circuit’s decision to revive the University of Pennsylvania’s gene therapy patent, since the cell is man-made and it does not occur naturally. Ramy says that the decision "confirms that the more details about utility and the patents, the better, because that is something that the court focused on."
The full article can be found here.